keyword
MENU ▼
Read by QxMD icon Read
search

Fibrotest

keyword
https://www.readbyqxmd.com/read/29709217/glycogenic-hepatopathy
#1
Johad Khoury, Yaniv Zohar, Naim Shehadeh, Tarek Saadi
BACKGROUND: Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus, most commonly type 1, expressed as right upper quadrant abdominal pain, hepatomegaly and increased liver enzymes. The diagnosis may be difficult, because laboratory and imaging tests are not pathognomonic. Although GH may be suggested based on clinical presentation and imaging studies, the gold standard for diagnosis is a liver biopsy, showing a significant accumulation of glycogen within the hepatocytes...
April 2018: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/29500489/potent-viral-suppression-and-improvements-in-alpha-fetoprotein-and-measures-of-fibrosis-in-japanese-patients-receiving-a-daclatasvir-asunaprevir-beclabuvir-fixed-dose-combination-for-the-treatment-of-hcv-genotype-1-infection
#2
Norio Akuta, Joji Toyota, Yoshiyasu Karino, Fusao Ikeda, Akio Ido, Katsuaki Tanaka, Koichi Takaguchi, Atsushi Naganuma, Eiichi Tomita, Kazuaki Chayama, Shigetoshi Fujiyama, Yukiko Inada, Hitoshi Yoshiji, Hideaki Watanabe, Hiroki Ishikawa, Fiona McPhee, Stephanie Noviello, Hiromitsu Kumada
BACKGROUND: In the UNITY-3 study, 96% sustained virologic response (SVR12) rate was observed in Japanese patients with hepatitis C virus (HCV) genotype (GT)-1 infection treated for 12 weeks with fixed-dose daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO). As HCV clearance may improve liver outcomes, we assessed hepatic fibrosis and alpha-fetoprotein (AFP), a hepatocellular carcinoma risk marker, pre- and post-treatment in UNITY-3. METHODS: Treatment-naive or interferon-experienced UNITY-3 patients with HCV GT-1 who received twice-daily DCV-TRIO were assessed for fibrosis [FibroTest; FibroScan; fibrosis-4 index (FIB-4), aspartate-aminotransferase-to-platelet-ratio index] and AFP at baseline and Weeks 4 (FIB-4 only), 12 or 24 post-treatment...
March 2, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29406435/diagnostic-performance-of-a-new-noninvasive-test-for-nonalcoholic-steatohepatitis-using-a-simplified-histological-reference
#3
Thierry Poynard, Mona Munteanu, Frederic Charlotte, Hugo Perazzo, Yen Ngo, Olivier Deckmyn, Raluca Pais, Wassil Merrouche, Victor de Ledinghen, Philippe Mathurin, Vlad Ratziu
BACKGROUND: One of the unmet needs in patients with metabolic risks is the prediction of metabolic liver disease (MLD) by noninvasive tests (NITs). OBJECTIVE: The primary aim of this study was to construct a new quantitative test for the diagnosis of nonalcoholic steatohepatitis (NASH) using a simplified histological definition. PATIENTS AND METHODS: As a reference, we used a simplified histological definition of NASH derived from the FLIP-CRN-definition that does not require the presence of steatosis and the presence of both lobular inflammation and ballooning...
May 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29317276/accuracy-of-the-enhanced-liver-fibrosis-test-vs-fibrotest-elastography-and-indirect-markers-in-detection-of-advanced-fibrosis-in-patients-with-alcoholic-liver-disease
#4
COMPARATIVE STUDY
Maja Thiele, Bjørn Stæhr Madsen, Janne Fuglsang Hansen, Sönke Detlefsen, Steen Antonsen, Aleksander Krag
BACKGROUND & AIMS: Alcohol is the leading cause of cirrhosis and liver-related mortality, but we lack serum markers to detect compensated disease. We compared the accuracy of the Enhanced Liver Fibrosis test (ELF), the FibroTest, liver stiffness measurements (made by transient elastography and 2-dimensional shear-wave elastography), and 6 indirect marker tests in detection of advanced liver fibrosis (Kleiner stage ≥F3). METHODS: We performed a prospective study of 10 liver fibrosis markers (patented and not), all performed on the same day...
April 2018: Gastroenterology
https://www.readbyqxmd.com/read/29287080/serum-apolipoprotein-a1-and-haptoglobin-in-patients-with-suspected-drug-induced-liver-injury-dili-as-biomarkers-of-recovery
#5
Valentina Peta, Chantal Tse, Hugo Perazzo, Mona Munteanu, Yen Ngo, An Ngo, Nittia Ramanujam, Lea Verglas, Maxime Mallet, Vlad Ratziu, Dominique Thabut, Marika Rudler, Vincent Thibault, Ina Schuppe-Koistinen, Dominique Bonnefont-Rousselot, Bernard Hainque, Françoise Imbert-Bismut, Michael Merz, Gerd Kullak-Ublick, Raul Andrade, Florian van Boemmel, Eckart Schott, Thierry Poynard
BACKGROUND: There is a clear need for better biomarkers of drug-induced-liver-injury (DILI). AIMS: We aimed to evaluate the possible prognostic value of ActiTest and FibroTest proteins apoliprotein-A1, haptoglobin and alpha-2-macroglobulin, in patients with DILI. METHODS: We analyzed cases and controls included in the IMI-SAFE-T-DILI European project, from which serum samples had been stored in a dedicated biobank. The analyses of ActiTest and FibroTest had been prospectively scheduled...
2017: PloS One
https://www.readbyqxmd.com/read/29247558/european-association-for-the-study-of-the-liver-easl-european-association-for-the-study-of-diabetes-easd-and-european-association-for-the-study-of-obesity-easo-clinical-practice-recommendations-for-the-management-of-non-alcoholic-fatty-liver-disease-evaluation
#6
A L Sberna, B Bouillet, A Rouland, M C Brindisi, A Nguyen, T Mouillot, L Duvillard, D Denimal, R Loffroy, B Vergès, P Hillon, J M Petit
AIMS: To evaluate the application of the recently proposed recommendations by the European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease in people with Type 2 diabetes. METHODS: A total of 179 people with Type 2 diabetes were included in this study. Liver fat content (assessed using proton magnetic resonance spectroscopy), fatty liver index score, non-alcoholic fatty liver disease fibrosis score, and SteatoTest and FibroTest scores were determined...
March 2018: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/29225775/fibromax-based-nonalcoholic-fatty-liver-disease-in-chronic-obstructive-pulmonary-disease-patients-with-obstructive-sleep-apnea-methodological-considerations
#7
Denis Monneret
The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea (OSA) has been well demonstrated, but remains to be evidenced in chronic obstructive pulmonary disease (COPD). Recently, Viglino et al. (Eur Respir J, 2017) attempted to determine the prevalence of liver fibrosis, steatosis and nonalcoholic steatohepatitis (NASH) in COPD patients, some of whom had OSA, basing the NAFLD diagnostic on three circulating biomarker-based liver scores: the FibroTest, SteatoTest and NashTest, from the Fibromax® panel...
2017: F1000Research
https://www.readbyqxmd.com/read/29154965/non-invasive-assessment-of-non-alcoholic-fatty-liver-disease-clinical-prediction-rules-and-blood-based-biomarkers
#8
REVIEW
Eduardo Vilar-Gomez, Naga Chalasani
The correct identification of patients at increased risk of non-alcoholic steatohepatitis (NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver disease (NAFLD). Since liver biopsy is invasive, expensive and prone to sampling error, several clinical prediction rules and blood-based biomarkers have been developed as attractive and affordable alternatives for identification of patients at high risk of NASH and advanced fibrosis. Current biomarkers constitute predictive models (e...
February 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/28862188/interferon-%C3%AE-inducible-protein-10-in-chronic-hepatitis-c-correlations-with-insulin-resistance-histological-features-sustained-virological-response
#9
Dana Crisan, Mircea Dan Grigorescu, Corina Radu, Alina Suciu, Mircea Grigorescu
BACKGROUND & OBJECTIVES: One of the multiple factors contributing to virological response in chronic hepatitis C (CHC) is interferon-gamma-inducible protein-10 (IP-10). Its level reflects the status of interferon-stimulated genes, which in turn is associated with virological response to antiviral therapy. The aim of this study was to evaluate the role of serum IP-10 levels on sustained virological response (SVR) and the association of this parameter with insulin resistance (IR) and liver histology...
April 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28756625/sofosbuvir-velpatasvir-in-patients-with-hepatitis-c-virus-genotypes-1-6-and-compensated-cirrhosis-or-advanced-fibrosis
#10
Tarik Asselah, Stefan Bourgeois, Stephen Pianko, Stefan Zeuzem, Mark Sulkowski, Graham R Foster, Lingling Han, John McNally, Anu Osinusi, Diana M Brainard, G Mani Subramanian, Edward J Gane, Jordan J Feld, Alessandra Mangia
BACKGROUND & AIMS: Patients with chronic hepatitis C virus infection and advanced fibrosis (Metavir F3) or cirrhosis (Metavir F4) have been identified as a priority group for immediate treatment. We evaluated the safety and efficacy of sofosbuvir-velpatasvir in patients with hepatitis C virus genotype 1-6 infection and compensated cirrhosis or advanced fibrosis. METHODS: This retrospective analysis included 501 patients with compensated cirrhosis or advanced fibrosis (F3/F4), as defined by >0...
March 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28692443/a-single-test-combining-blood-markers-and-elastography-is-more-accurate-than-other-fibrosis-tests-in-the-main-causes-of-chronic-liver-diseases
#11
COMPARATIVE STUDY
Alexandra Ducancelle, Vincent Leroy, Julien Vergniol, Nathalie Sturm, Brigitte Le Bail, Jean Pierre Zarski, Eric Nguyen Khac, Dominique Salmon, Victor de Ledinghen, Paul Calès
BACKGROUND AND GOAL: International guidelines suggest combining a blood test and liver stiffness measurement (LSM) to stage liver fibrosis in chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD). Therefore, we compared the accuracies of these tests between the main etiologies of chronic liver diseases. STUDY: Overall, 1968 patients were included in 5 etiologies: CHC: 698, chronic hepatitis B: 152, human immunodeficiency virus/CHC: 628, NAFLD: 225, and alcoholic liver disease (ALD): 265...
August 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28661201/diagnostic-accuracy-of-the-coopscore-%C3%A2-to-predict-liver-fibrosis-in-human-immunodeficiency-virus-hepatitis-b-virus-co-infection
#12
Ludmia Taibi, Anders Boyd, Nelly Bosselut, Julie Bottero, Jérôme Guéchot, Karine Lacombe, Elisabeth Lasnier, Bruno Baudin, Michel Vaubourdolle
Background Non-invasive methods for assessing liver fibrosis are increasingly used as an alternative to liver biopsy. Recently, a score-based biochemical blood test (Coopscore© ) was developed in a cohort of patients chronically infected with hepatitis C virus, showing higher diagnostic performances than Fibrometer®, Fibrotest®, Hepascore® and Fibroscan™. Here, we assess its performance in patients co-infected with the human immunodeficiency virus and hepatitis B virus. Methods Ninety-seven human immunodeficiency virus/hepatitis B virus co-infected patients with liver biopsies were included from a previously described cohort...
March 2018: Annals of Clinical Biochemistry
https://www.readbyqxmd.com/read/28596431/nonalcoholic-fatty-liver-disease-in-chronic-obstructive-pulmonary-disease
#13
Damien Viglino, Ingrid Jullian-Desayes, Mélanie Minoves, Judith Aron-Wisnewsky, Vincent Leroy, Jean-Pierre Zarski, Renaud Tamisier, Marie Joyeux-Faure, Jean-Louis Pépin
Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and mortality. Low-grade inflammation, oxidative stress and ectopic fat, common features of chronic obstructive pulmonary disease (COPD), might contribute to the development of NAFLD.We aimed to investigate the prevalence of NAFLD and to evaluate the relationship between various types of liver damage and COPD severity, comorbidities and circulating inflammatory cytokines. Validated noninvasive tests (FibroMax: SteatoTest, NashTest and FibroTest) were used to assess steatosis, nonalcoholic steatohepatitis (NASH) and liver fibrosis...
June 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28530647/stage-of-liver-fibrosis-in-patients-with-congenital-bleeding-disorders-and-infected-with-hepatitis-c-virus
#14
Marta Kucharska, Urszula Zaleska-Dorobisz, Aleksandra Szymczak, Marcin Inglot, Weronika Rymer, Małgorzata Zalewska, Krzysztof Małyszczak, Małgorzata Kuliszkiewicz-Janus, Małgorzata Inglot
INTRODUCTION    Hepatitis C virus (HCV) is the major cause of chronic liver disease in patients with hemophilia. As liver biopsy should not be routinely used in them, possibilities of accurate assessment of the fibrosis stage have been very limited until recently. OBJECTIVES    The aim of the study was to determine the stage of liver fibrosis in HCV-infected hemophiliacs with use of non-invasive methods of fibrosis assessment and to analyze the influence of risk factors on liver fibrosis.  PATIENTS AND METHODS    The study included 71 HCV-infected patients with hemophilia and other congenital bleeding disorders...
May 22, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28464883/late-presentation-of-chronic-viral-hepatitis-for-medical-care-a-consensus-definition
#15
Stefan Mauss, Stanislas Pol, Maria Buti, Erika Duffell, Charles Gore, Jeffrey V Lazarus, Hilje Logtenberg-van der Grient, Jens Lundgren, Antons Mozalevskis, Dorthe Raben, Eberhard Schatz, Stefan Wiktor, Jürgen K Rockstroh
INTRODUCTION: We present two consensus definitions of advanced and late stage liver disease being used as epidemiological tools. These definitions can be applied to assess the morbidity caused by liver diseases in different health care systems. We focus is on hepatitis B and C virus infections, because effective and well tolerated treatments for both of these infections have greatly improved our ability to successfully treat and prevent advanced and late stage disease, especially if diagnosed early...
May 3, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28439936/hiv-positive-men-who-have-sex-with-men-are-at-high-risk-of-development-of-significant-liver-fibrosis-after-an-episode-of-acute-hepatitis-c
#16
K Steininger, A Boyd, S Dupke, I Krznaric, A Carganico, M Munteanu, S Neifer, M Schuetze, M Obermeier, K Arasteh, A Baumgarten, P Ingiliz
Acute hepatitis C virus infection remains a major health concern in human immunodeficiency virus(HIV)-infected men who have sex with men (MSM). New direct-acting antiviral agent (DAA) combination therapy has not yet been approved for the treatment for acute hepatitis C virus(HCV), thereby potentially causing deferral of HCV treatment. Therefore, we aimed to study the course of liver disease after an episode of acute HCV. This study is a retrospective single-centre cohort of HIV-positive MSM with acute HCV infection...
April 25, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28404158/prevalence-of-clinically-significant-liver-disease-within-the-general-population-as-defined-by-non-invasive-markers-of-liver-fibrosis-a-systematic-review
#17
REVIEW
Rebecca Harris, David J Harman, Timothy R Card, Guruprasad P Aithal, Indra Neil Guha
As of 2016, there is no evidence-based pathway to stratify the risk of chronic liver disease in a general population setting. Non-invasive tests of liver fibrosis might provide a mechanism for earlier diagnosis. These tests have been extensively validated in the hospital setting but their performance in a general population setting is unclear. We did a systematic review of non-invasive tests used to stratify patients at risk of clinically significant liver disease in a general population setting and report the prevalence of chronic liver disease as defined by these tests...
April 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28396861/non-invasive-investigations-for-the-diagnosis-of-fontan-associated-liver-disease-in-pediatric-and-adult-fontan-patients
#18
Amyna Fidai, Frederic Dallaire, Nanette Alvarez, Yvonne Balon, Robin Clegg, Michael Connelly, Frank Dicke, Deborah Fruitman, Joyce Harder, Kimberley Myers, David J Patton, Tim Prieur, Erika Vorhies, Robert P Myers, Steven R Martin, Steven C Greenway
Fontan-associated liver disease (FALD) is a serious complication related to the chronically elevated venous pressure and low cardiac output of this abnormal circulation. However, diagnostic markers for this condition are limited. We hypothesized that specific tests for fibrosis developed for other chronic liver diseases would identify a higher prevalence of FALD than ultrasound and standard laboratory tests and that identified abnormalities would correlate with time post-Fontan. In this cross-sectional study, we assessed 19 children (average age 8...
2017: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28391883/childhood-adult-onset-lysosomal-acid-lipase-deficiency-a-serious-metabolic-and-vascular-phenotype-beyond-liver-disease-four-new-pediatric-cases
#19
Pierre Poinsot, Sophie Collardeau Frachon, Lioara Restier, André Sérusclat, Mathilde Di Filippo, Sybil Charrière, Philippe Moulin, Alain Lachaux, Noel Peretti
BACKGROUND: The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset LALD) is a rare genetic disease. Children present severe fatty liver disease with early cirrhosis. Before enzyme replacement therapy, statins were the standard treatment to improve the severe dyslipidemia. However, late-onset LALD should be considered as a systemic metabolic disease: chronic hyper-low-density lipoprotein and hypo-high-density lipoprotein cholesterolemia induces early atherosclerosis in addition to the liver morbidity...
January 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28387018/transient-elastography-alone-and-in-combination-with-fibrotest%C3%A2-for-the-diagnosis-of-hepatic-fibrosis-in-alcoholic-liver-disease
#20
Cosmin Sebastian Voican, Alexandre Louvet, Jean-Baptiste Trabut, Micheline Njiké-Nakseu, Sébastien Dharancy, Andrea Sanchez, Marion Corouge, Karima Lamouri, Amandine Lebrun, Axel Balian, Sophie Prévot, Mounia Lachgar, Sophie Maitre, Hélène Agostini, Philippe Mathurin, Gabriel Perlemuter, Sylvie Naveau
BACKGROUND & AIMS: The reliability of transient elastography (TE) to assess liver fibrosis is insufficiently validated in alcoholic liver disease (ALD). We aimed to validate the diagnostic utility of TE for liver fibrosis in patients with excessive alcohol consumption and evaluate whether Fibrotest® adds diagnostic value relative to or in combination with TE. METHODS: We conducted a multicentre prospective study on a total of 217 heavy drinkers with high serum aminotransferase levels...
November 2017: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
14688
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"